logo
  

Gentex Q3 Profit Misses Estimates; Cuts Outlook

Gentex Corporation (GNTX) said the effects of the electronic component shortages worsened during its third quarter. On a quarter-over-quarter basis, global light vehicle production in its primary regions of Europe, North America, Japan/Korea and China decreased 23% compared to prior year quarter. Net income declined year-on-year primarily due to changes in sales, gross margins and operating profits. The gross margin for the third quarter of 2021 was at 35.3%, below the company's original forecasts, primarily impacted by the lower sales levels stemming from the decline in light vehicle production in primary regions. Auto-dimming mirror unit shipments fell 7% during the quarter from a year ago.

Earnings per share was $0.32, compared to $0.48, previous year. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $0.37, for the quarter. Analysts' estimates typically exclude special items. Net income was $76.7 million, compared to $117.1 million, last year.

Net sales were $399.6 million, compared to $474.6 million, previous year. Analysts expected revenue of $434.57 million, for the quarter. Automotive net sales were $391.3 million, compared to $464.7 million, prior year.

The company also issued updated guidance estimates for the second half of 2021. Gross margin is now estimated in a range of 35% - 36%, revised from prior guidance range of 37.5% - 38.5%. Revenue is now projected to be in a range of $770 million - $840 million, updated from prior guidance range of $970 million - $1.07 billion.

Based on the mid-October 2021 light vehicle production estimates for 2022, the company expects its revenue for calendar year 2022 to be approximately 15% - 20% higher than the updated 2021 revenue estimates of $1.68 - $1.75 billion.

Shares of Gentex were down 3% in pre-market trade on Friday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Teleflex Inc., a provider of medical technologies for critical care and surgery, is recalling Arrow-Trerotola Over-The-Wire PTD Kit Percutaneous Thrombolytic Device: 7FR, the U.S. Food and Drug Administration said. The Arrow-Trerotola Percutaneous Thrombolytic Device or PTD Catheter, in conjunction with the Arrow Rotator Drive Unit, permits mechanical declotting of native arterio-venous or AV... Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated..
RELATED NEWS
Follow RTT